Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-2.40 Insider Own0.10% Shs Outstand2.22B Perf Week-0.37%
Market Cap122.99B Forward P/E7.19 EPS next Y7.84 Insider Trans-16.08% Shs Float2.22B Perf Month-5.12%
Income-5405.00M PEG- EPS next Q1.82 Inst Own75.50% Short Float0.91% Perf Quarter-14.16%
Sales45.47B P/S2.70 EPS this Y-298.80% Inst Trans0.16% Short Ratio1.66 Perf Half Y-13.05%
Book/sh16.77 P/B3.36 EPS next Y4.41% ROA-4.80% Target Price72.84 Perf Year-8.84%
Cash/sh7.25 P/C7.77 EPS next 5Y5.97% ROE-14.50% 52W Range53.22 - 69.75 Perf YTD-9.21%
Dividend1.96 P/FCF12.00 EPS past 5Y-44.40% ROI-10.10% 52W High-19.25% Beta0.58
Dividend %3.48% Quick Ratio1.40 Sales past 5Y20.80% Gross Margin79.00% 52W Low5.82% ATR1.26
Employees30250 Current Ratio1.50 Sales Q/Q10.30% Oper. Margin-10.30% RSI (14)43.53 Volatility2.58% 1.90%
OptionableYes Debt/Eq1.20 EPS Q/Q-15.70% Profit Margin-11.90% Rel Volume1.49 Prev Close55.41
ShortableYes LT Debt/Eq1.07 EarningsOct 27 BMO Payout- Avg Volume12.18M Price56.32
Recom2.00 SMA20-2.65% SMA50-3.26% SMA200-11.05% Volume18,125,902 Change1.64%
Nov-19-21Initiated BMO Capital Markets Outperform $72
Nov-01-21Downgrade Argus Buy → Hold
Jul-27-21Resumed Truist Buy $74
Apr-30-21Downgrade Morgan Stanley Overweight → Equal-Weight $70 → $62
Apr-13-21Upgrade Truist Hold → Buy
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
Dec-04-21 08:20PM  
08:55AM  
Dec-03-21 11:45PM  
10:50PM  
12:33PM  
10:11AM  
06:59AM  
06:10AM  
05:51AM  
Dec-02-21 10:50PM  
02:13PM  
10:35AM  
09:02AM  
Dec-01-21 11:16PM  
08:41PM  
07:53PM  
06:25PM  
06:22PM  
07:33AM  
Nov-30-21 11:34PM  
03:52PM  
11:57AM  
11:30AM  
Nov-29-21 11:44PM  
06:10PM  
09:21AM  
06:59AM  
05:17AM  
Nov-27-21 05:51AM  
Nov-26-21 10:50PM  
12:42PM  
Nov-25-21 10:45PM  
05:55AM  
Nov-24-21 11:34PM  
04:16PM  
11:21AM  
12:06AM  
Nov-23-21 08:55AM  
06:59AM  
Nov-22-21 10:56PM  
01:30PM  
10:27AM  
07:30AM  
Nov-19-21 10:00PM  
12:33PM  
11:00AM  
09:02AM  
07:42AM  
Nov-18-21 10:50PM  
03:08PM  
07:55AM  
06:59AM  
Nov-17-21 11:50PM  
07:38PM  
02:52PM  
10:25AM  
Nov-16-21 10:34PM  
02:25PM  
Nov-15-21 10:50PM  
05:24PM  
02:00PM  
11:18AM  
07:00AM  
06:35AM  
Nov-14-21 10:04PM  
03:00PM  
Nov-13-21 11:00AM  
09:24AM  
07:23AM  
05:51AM  
Nov-12-21 10:50PM  
04:57PM  
10:07AM  
Nov-11-21 07:45PM  
06:05PM  
08:22AM  
04:55AM  
Nov-10-21 10:50PM  
03:41PM  
06:59AM  
06:57AM  
Nov-09-21 11:56PM  
12:45PM  
09:30AM  
Nov-08-21 11:28PM  
01:30PM  
11:18AM  
10:12AM  
06:59AM  
06:59AM  
05:51AM  
Nov-06-21 07:03AM  
Nov-05-21 10:50PM  
11:00AM  
10:10AM  
Nov-04-21 09:25PM  
04:35PM  
10:16AM  
06:05AM  
02:14AM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
von Autenried PaulEVP, Chief Information OfficerNov 24Sale56.9217,353987,73363,536Nov 24 05:25 PM
von Autenried PaulEVP, Chief Information OfficerNov 23Sale57.4715,418886,07280,889Nov 24 05:25 PM
von Autenried PaulEVP, Chief Information OfficerNov 22Sale57.1718,3631,049,81396,307Nov 24 05:25 PM
Caforio GiovanniBoard Chair and CEOSep 20Sale60.6425,0001,516,000483,980Sep 22 05:19 PM
Elkins David VEVP, Chief Financial OfficerAug 12Option Exercise48.4970,0003,394,300139,699Aug 16 05:51 PM
Elkins David VEVP, Chief Financial OfficerAug 12Sale66.9599,6916,674,49769,699Aug 16 05:51 PM
Powell AnnEVP, Chief Human ResourcesAug 03Sale68.5723,2801,596,31047,613Aug 04 04:46 PM
Caforio GiovanniChairman and CEOAug 02Sale68.5820,0001,371,600508,980Aug 04 04:47 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,4030133,435Aug 03 04:55 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Option Exercise58.49150,9678,830,108187,617Aug 03 04:50 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Jul 30Sale67.902,466167,44113,777Aug 03 04:56 PM
LEUNG SANDRAEVP, General CounselJul 30Sale68.0429,3901,999,696339,967Aug 03 04:54 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Sale68.07158,39310,782,15436,650Aug 03 04:50 PM
von Autenried PaulEVP, Chief Information OfficerJul 30Sale68.0625,0001,701,375114,670Aug 03 04:49 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,069015,045Jul 06 04:38 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,356016,538Jul 06 04:38 PM
Haller Julia ADirectorJun 13Option Exercise0.00902010,670Jun 14 06:56 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.00902012,501Jun 14 06:56 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,154010,223Jun 04 04:36 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94909,768Jun 04 04:35 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 10Sale65.2515,000978,75031,956May 11 04:39 PM
Eid JosephSVP,Head Glob. Medical AffairsMay 10Sale65.001,11872,6708,069May 11 04:39 PM
VESSEY RUPERTEVP, Research & Early Dev.May 08Option Exercise0.0017,245062,384May 11 04:38 PM
VESSEY RUPERTEVP, Research & Early Dev.May 05Sale64.2930,5461,963,80245,139May 07 04:56 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 05Sale64.213,119200,27116,243May 07 04:57 PM
Mily ElizabethEVP, Strategy & BDApr 01Option Exercise0.006,34605,380Apr 02 01:14 PM
Caforio GiovanniChairman and CEOMar 22Sale62.2025,0001,555,000528,980Mar 24 04:41 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,404019,811Mar 12 06:59 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0025,215041,325Mar 12 06:59 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00200,7090603,187Mar 12 06:59 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.006,13409,862Mar 12 06:58 PM
Elkins David VEVP, Chief Financial OfficerMar 10Option Exercise0.008,025091,211Mar 12 06:57 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10Option Exercise0.004,18909,082Mar 12 06:56 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0050,3730383,564Mar 12 06:52 PM
Santiago Karen MurphySVP & ControllerMar 10Option Exercise0.007,483014,717Mar 12 06:50 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0029,835076,125Mar 12 06:51 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,3020143,800Mar 12 06:50 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 10Option Exercise0.007,423079,051Mar 12 06:50 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0031,575053,018Mar 12 06:50 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579091,759Mar 03 05:27 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 01Option Exercise0.0023,349080,572Mar 03 05:26 PM
VESSEY RUPERTEVP, Research & Early Dev.Feb 04Option Exercise0.003,592058,409Feb 08 07:28 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0020,624079,111Jan 05 08:13 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 31Option Exercise0.0025,866068,074Jan 05 08:14 PM
AHMED NADIMEVP and President, HematologyDec 31Option Exercise0.0014,946046,549Jan 05 08:13 PM